Allogene Therapeutics, Inc.·3

Sep 20, 6:25 PM ET

PF Equity Holdings 2 B.V. 3

3 · Allogene Therapeutics, Inc. · Filed Sep 20, 2021

Insider Transaction Report

Form 3
Period: 2021-09-10
Holdings
  • Common Stock

    22,032,040
Footnotes (1)
  • [F1]Shares acquired from its parent entity, Pfizer Inc. for no cash consideration.

Documents

2 files